Genentech’s biosimilar complaint against Amgen dismissed
Judge Sleet of the District of Delaware has dismissed Genentech’s biosimilar complaint against Amgen for lack of subject matter jurisdiction, and granted 45 days for an amended complaint to be filed
Genentech’s complaint alleging Amgen failed to
comply with the Biologics Price Competition and Innovation Act
(BPCIA) has been dismissed by Judge Sleet of the District of
Delaware. Sleet dismissed the complaint without prejudice on
March 1 and gave Genentech 45...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.